Bayer (BAYRY)
(Delayed Data from OTC)
$7.39 USD
+0.12 (1.65%)
Updated Apr 26, 2024 03:59 PM ET
4-Sell of 5 4
B Value A Growth F Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BAYRY 7.39 +0.12(1.65%)
Will BAYRY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BAYRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BAYRY
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
BAYRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
Thermo Fisher (TMO) Inks Deal to Develop Companion Diagnostics
Other News for BAYRY
Bayer goes ex dividend Monday
GLOBAL BRIEFING: Yen slumps to new multi-decade low as BoJ stands pat
Missouri House backs legal shield for weedkiller maker facing thousands of cancer-related lawsuits
IN BRIEF: Bayer secures licencing rights for new AlphaBio insecticide
IN BRIEF: Bayer signs renewable power supply deal for German sites